According to CoinMeta, recently, the National Medical Products Administration approved the marketing of Oflorglurone Calcium Tablets (trade name: Muyouda), a Class 1 innovative drug declared by EliLilly Nederland B.V. This medication is indicated for the long-term weight management of adults with an initial Body Mass Index (BMI) that meets the following criteria, on top of controlled diet and increased exercise: ≥30 kg / m2 (obese), or ≥27 kg / m2 to ≤lt; 30 kg / m2 (overweight) accompanied by at least one weight-related comorbidity (such as hypertension, dyslipidemia, hyperglycemia, obstructive sleep apnea syndrome, cardiovascular disease, etc.). The launch of this drug provides patients with a new treatment option.